Daniel Palmer

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6202249/daniel-palmer-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

25	1,975	18	2 6
papers	citations	h-index	g-index
26	2,191 ext. citations	10.7	4.02
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
25	C-Terminal lactamization of peptides. <i>Chemical Communications</i> , 2021 , 57, 895-898	5.8	3
24	Design and Combinatorial Development of Shield-1 Peptide Mimetics Binding to Destabilized FKBP12. <i>ACS Combinatorial Science</i> , 2020 , 22, 156-164	3.9	2
23	MC4R as a Target for Pharmacotherapeutic Treatment of Obesity and Type 2 Diabetes 2020 , 935-946		
22	Identification of a novel scaffold for a small molecule GPR139 receptor agonist. <i>Scientific Reports</i> , 2019 , 9, 3802	4.9	6
21	MC4R Agonists: Structural Overview on Antiobesity Therapeutics. <i>Trends in Pharmacological Sciences</i> , 2018 , 39, 402-423	13.2	31
20	Click-Chemistry-Mediated Synthesis of Selective Melanocortin Receptor 4 Agonists. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 8716-8730	8.3	15
19	Comparative studies of adhesion peptides based on l- or d-amino acids. <i>Journal of Peptide Science</i> , 2016 , 22, 642-646	2.1	
18	Redundancy and interaction of thrombin- and collagen-mediated platelet activation in tail bleeding and carotid thrombosis in mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology,</i> 2014 , 34, 2563-9	9.4	26
17	High-resolution crystal structure of human protease-activated receptor 1. <i>Nature</i> , 2012 , 492, 387-92	50.4	353
16	TMEM16F forms a Ca2+-activated cation channel required for lipid scrambling in platelets during blood coagulation. <i>Cell</i> , 2012 , 151, 111-22	56.2	292
15	Wnt/Etatenin signaling is differentially regulated by Giproteins and contributes to fibrous dysplasia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 20101-6	11.5	71
14	The sphingosine 1-phosphate receptor S1PImaintains the homeostasis of germinal center B cells and promotes niche confinement. <i>Nature Immunology</i> , 2011 , 12, 672-80	19.1	184
13	Bone marrow-derived cells contribute to vascular endothelial growth factor-induced angiogenesis in the adult mouse brain by supplying matrix metalloproteinase-9. <i>Stroke</i> , 2011 , 42, 453-8	6.7	37
12	Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 18605-10	11.5	38
11	Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. <i>Journal of Clinical Investigation</i> , 2009 , 119, 1871-9	15.9	272
10	Inhibition of the ADP/P2Y12 Pathway Confers Additional Protection against Arterial Thrombosis in PAR-4 Deficient Mice. <i>Blood</i> , 2008 , 112, 3933-3933	2.2	
9	Neutrophil depletion decreases VEGF-induced focal angiogenesis in the mature mouse brain. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1853-60	7.3	48

LIST OF PUBLICATIONS

8	Protein kinase A phosphorylation of human phosphodiesterase 3B promotes 14-3-3 protein binding and inhibits phosphatase-catalyzed inactivation. <i>Journal of Biological Chemistry</i> , 2007 , 282, 9411-9419	5.4	36
7	Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. <i>Molecular Pharmacology</i> , 2003 , 64, 533-46	4.3	260
6	Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease. <i>Diabetes</i> , 2002 , 51, 1194-200	0.9	26
5	Reduced phosphodiesterase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle cells: implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues. <i>Molecular Pharmacology</i> , 2002 , 61, 1033-40	4.3	31
4	Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues. <i>Molecular Pharmacology</i> , 2000 , 58, 247-52	4.3	54
3	Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells. <i>Journal of</i>	5.4	64
2	Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. <i>Circulation Research</i> , 1998 , 82, 852-61	15.7	78
1	Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. <i>British Journal of Pharmacology</i> , 1997 , 122, 233-40	8.6	48